1. Systematic review and network meta-analysis: effect of biologics on radiographic progression in rheumatoid arthritis
- Author
-
Yekaterina Butylkova, Martha Skup, Vishvas Garg, J. Kalabic, Alexandra G Ellis, and Erin Murray
- Subjects
musculoskeletal diseases ,Oncology ,medicine.medical_specialty ,Network Meta-Analysis ,Antibodies, Monoclonal, Humanized ,Drug Administration Schedule ,Arthritis, Rheumatoid ,03 medical and health sciences ,chemistry.chemical_compound ,0302 clinical medicine ,Tocilizumab ,Internal medicine ,medicine ,Adalimumab ,Humans ,030212 general & internal medicine ,skin and connective tissue diseases ,030203 arthritis & rheumatology ,Biological Products ,business.industry ,Tumor Necrosis Factor-alpha ,Health Policy ,Abatacept ,Antibodies, Monoclonal ,Bayes Theorem ,medicine.disease ,Golimumab ,Methotrexate ,Treatment Outcome ,chemistry ,Rheumatoid arthritis ,Meta-analysis ,Antirheumatic Agents ,Disease Progression ,Rituximab ,Drug Therapy, Combination ,Female ,business ,medicine.drug - Abstract
Aim: To evaluate the comparative effectiveness of biologics in inhibiting radiographic progression among rheumatoid arthritis (RA) patients. Materials & methods: Bayesian network meta-analysis of published trials investigating the USA FDA approved biologics treatment in RA patients, using methotrexate (MTX) as the reference comparator. Results: Nine trials met the inclusion criteria for base case analysis. Compared with MTX, most biologics (except golimumab) + MTX had significantly lower rates of radiographic progression at 1 year. Mean difference in radiographic progression rates between MTX monotherapy and biologics + MTX was highest for adalimumab + MTX (-3.8) and lowest for tocilizumab + MTX (-0.7). Inhibition of radiographic progression was sustained. Conclusion: Biologics inhibit radiographic progression in patients with RA at 1 year; however, published evidence beyond 1 year is limited.
- Published
- 2018